Bhanuprasad Venkatesulu1, Supriya Mallick2, Prashanth Giridhar1, Ashish Dutt Upadhyay3, Goura K Rath1. 1. Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India. 2. Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India. drsupriyamallick@gmail.com. 3. Department of Bio-Statistics, All India Institute of Medical Sciences, New Delhi, India.
Abstract
INTRODUCTION: Head and neck extramedullary plasmacytoma is a rare localized plasma cell neoplasm. We intended to perform this review of the published literature to assess the demographic profile, pattern of care and survival outcomes. METHODS: Two authors independently searched PubMed, Google search and Cochrane library for eligible studies from 1950 till July 1, 2016, published in English language. RESULTS: Median age of the cohort was 57 years (range 11-85). Site-wise distributions were paranasal sinuses 22.3% (70), nasal cavity 17.5% (55), nasopharynx 10.8% (34). Median size of SEMP was 3 cm (range 0.3-12 cm). Treatment distribution was radiotherapy (RT) in 52% (164), surgery (S) 19% (60), chemotherapy (C) 5% (16), S + RT 23.49% (74),CRT 1.9% (6), S + C 0.6% (2), S + RT + C 0.95% (3).Radiation was used as a modality in 78.4%(247), surgery in 44.1%(139), chemotherapy in 4.8%(15). Median radiation dose used was 45 Gy with range 20-61 Gy. Median overall survival (OS) was 40 months (range 0.5-298). Median local progression-free survival was 36 months (range 0-298). Median myeloma relapse-free survival was 36 months (range 0.5-298). Five- and 10-year OS was 78.33 and 68.61%. Five-year cause-specific survival (CSS) and 10-year CSS was 90.15 and 83.31%. Five-year LPFS was 94.78%, and 10-year LPFS was 88.43%. Five-year myeloma progression-free survival was 84.46%, and 10-year myeloma PFS was 80.44%. The factors associated with risk of local relapse were site of disease (sinonasal), secretory EMP, type of treatment received (surgery + RT > RT alone > surgery on univariate analysis). Risk factors for myeloma relapse were coexisting diseases, site of disease (sinonasal), bony erosion, size of lesion > 5 cm and type of treatment received on univariate analysis. CONCLUSION: Our study shows that combined modality S + RT is superior compared to uni-modality in preventing local recurrence. Radiation dose of 45 Gy is optimal. Nodal irradiation has no impact on local recurrence.
INTRODUCTION: Head and neck extramedullary plasmacytoma is a rare localized plasma cell neoplasm. We intended to perform this review of the published literature to assess the demographic profile, pattern of care and survival outcomes. METHODS: Two authors independently searched PubMed, Google search and Cochrane library for eligible studies from 1950 till July 1, 2016, published in English language. RESULTS: Median age of the cohort was 57 years (range 11-85). Site-wise distributions were paranasal sinuses 22.3% (70), nasal cavity 17.5% (55), nasopharynx 10.8% (34). Median size of SEMP was 3 cm (range 0.3-12 cm). Treatment distribution was radiotherapy (RT) in 52% (164), surgery (S) 19% (60), chemotherapy (C) 5% (16), S + RT 23.49% (74),CRT 1.9% (6), S + C 0.6% (2), S + RT + C 0.95% (3).Radiation was used as a modality in 78.4%(247), surgery in 44.1%(139), chemotherapy in 4.8%(15). Median radiation dose used was 45 Gy with range 20-61 Gy. Median overall survival (OS) was 40 months (range 0.5-298). Median local progression-free survival was 36 months (range 0-298). Median myeloma relapse-free survival was 36 months (range 0.5-298). Five- and 10-year OS was 78.33 and 68.61%. Five-year cause-specific survival (CSS) and 10-year CSS was 90.15 and 83.31%. Five-year LPFS was 94.78%, and 10-year LPFS was 88.43%. Five-year myeloma progression-free survival was 84.46%, and 10-year myeloma PFS was 80.44%. The factors associated with risk of local relapse were site of disease (sinonasal), secretory EMP, type of treatment received (surgery + RT > RT alone > surgery on univariate analysis). Risk factors for myeloma relapse were coexisting diseases, site of disease (sinonasal), bony erosion, size of lesion > 5 cm and type of treatment received on univariate analysis. CONCLUSION: Our study shows that combined modality S + RT is superior compared to uni-modality in preventing local recurrence. Radiation dose of 45 Gy is optimal. Nodal irradiation has no impact on local recurrence.
Entities:
Keywords:
Chemotherapy; Head and neck; Myeloma; Plasmacytoma; Radiotherapy
Authors: Christine D'Aguillo; Resha S Soni; Chirag Gordhan; James K Liu; Soly Baredes; Jean Anderson Eloy Journal: Int Forum Allergy Rhinol Date: 2013-12-13 Impact factor: 3.858
Authors: Mahmut Ozsahin; Richard W Tsang; Philip Poortmans; Yazid Belkacémi; Michel Bolla; Fazilet Oner Dinçbas; Christine Landmann; Bernard Castelain; Jeroen Buijsen; Jürgen Curschmann; Sidney P Kadish; Anna Kowalczyk; Yavuz Anacak; Josef Hammer; Tan D Nguyen; Gabriela Studer; Rachel Cooper; Meriç Sengöz; Luciano Scandolaro; Abderrahim Zouhair Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-17 Impact factor: 7.038
Authors: P Galieni; M Cavo; G Avvisati; A Pulsoni; R Falbo; M A Bonelli; D Russo; M T Petrucci; A Bucalossi; S Tura Journal: Ann Oncol Date: 1995-09 Impact factor: 32.976
Authors: Tapan D Patel; Alejandro Vázquez; Moaz M Choudhary; David Kam; Soly Baredes; Jean Anderson Eloy Journal: Int Forum Allergy Rhinol Date: 2015-05-07 Impact factor: 3.858
Authors: Justin Komisarof; Jodi Lipof; Joseph DiTursi; Amit Chowdhry; Hae Yoon Grace Choung; W Richard Burack; Louis Constine; Frank Passero Journal: Case Rep Hematol Date: 2022-02-21